Big Shot: Developments in Prefilled Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Big Shot: Developments in Prefilled Syringes
Many companies are coming up with innovative materials and manufacturing methods to feed the growing demand for prefilled syringes.


Pharmaceutical Technology


"There are robotics for all the steps, it's just a matter of getting them more accepted into the industry," says Isberg. "Moving toward automated processes, such as handling nested tubs, provides consistency, and the technology is becoming cheaper and more standardized. You just have to get past the company's fear of automation so they can understand the advantages of it."

Because the entire process can take place inside a barrier system, engineers are redesigning automated equipment to be smaller and narrower so as to provide operators an easy reach across them if necessary. Barrier systems not only protect the product from contamination and product operators from potent compounds, they also may protect operators from the robotics units inside the system. Isolator and RABs systems may be equipped with "light curtains" that detect when operators place their hands in the gloves and shuts the machinery down. Barrier systems are also equipped with various online sensors for fill volume, headspace analysis, particulate detection, and visual inspection.

"Those are all integrated into the filling system," says Isberg. "A lot of this technology wasn't available 10 to 15 years ago."

Reference

1. B. Verjans, J. Thilly, and C. Vandecasserie, "A New Concept in Aseptic Filling: Closed-Vial Technology," Aseptic Processing, supplement to Pharm. Technol. (May 2005).

2. J. Zimmermann, "Advances in Aseptic Manufacturing," presented at PDA Emerging Manufacturing and Quality Control Technologies, San Diego, CA, Jan. 30, 2007.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here